1. Objective {#s0005}
============

Hypophosphatasia (HPP) is an inherited disorder characterized by defective bone and tooth mineralization, and a deficiency in tissue-non-specific alkaline phosphatase isoenzyme (TNSALP) activity \[[@bb0005]\]. The incidence of this disorder is not accurately known, but the birth prevalence of the most severe forms of HPP, i.e. perinatal and infantile, is estimated at 1:100,000 \[[@bb0010]\]. An estimate of 1:6370 has been suggested previously for less severe forms of HPP using molecular data \[[@bb0015]\].

TNSALP is a phosphomonoesterase of 507 residues that is anchored at its carboxyl terminus to the plasma membrane by a phosphatidylinositol-glycan moiety. This enzyme is physiologically active in its dimeric form and cleaves the extracellular substrates pyridoxal-5′-phosphate (PLP), phosphoethanolamine (PEA) and inorganic pyrophosphates (PPi) \[[@bb0005]\]. Low TNSALP activity has impacts on multiple systems, including the respiratory, central nervous, renal, musculoskeletal, and immune systems, and on dental structures \[[@bb0020]\].

HPP is caused by mutations in the liver/bone/kidney alkaline phosphatase (*ALPL*) gene encoding TNSALP \[[@bb0025],[@bb0030]\]. To date, 390 mutations have been identified in *ALPL* that show an association with HPP. (<http://www.sesep.uvsq.fr/03_hypo_mutations.php>). HPP symptoms are highly variable in terms of their clinical expression, and six clinical forms are currently recognized. These are based on the age at diagnosis and the severity of disease features including lethal perinatal, benign perinatal, infantile, childhood, adult, and odontohypophosphatasia (odonto-HPP) \[[@bb0030]\]. Enzyme replacement therapy (ERT) has recently been reported to be efficient and improve patient outcomes even in cases of life-threatening forms of HPP \[[@bb0035]\]. Although some genotype/phenotype correlations have been described for a portion of the *ALPL* mutations, the mechanisms underlying HPP remain incompletely understood, particularly in the mild forms of this disorder.

In our present study, we analyzed the clinical and genetic aspects of a small series of Japanese patients with mild HPP.

2. Material and methods {#s0010}
=======================

2.1. Informed consent and ethical approval {#s0015}
------------------------------------------

Informed consent was obtained from each patient and/or their family. The study protocol was approved by the Ethical Review Board for Human Genome Studies at Fujita Health University.

2.2. Clinical survey of mild HPP patients {#s0020}
-----------------------------------------

In our present study, mild HPP refers to childhood and adult HPP, odontohypophosphatasia, and perinatal benign HPP. Severe HPP denotes the perinatal and infantile forms. We reviewed the medical charts of 5 patients from 3 families who presented with mild HPP and had sufficient follow-up data. Patients 1 and 2 are siblings, and patient 4 is the daughter of patient 5. All of these cases had been referred to Fujita Health University Hospital for a detailed medical examination due to the premature loss of deciduous teeth. Our review of these cases included all available data from the physical examinations and medical care provided at the Fujita Health University Hospital.

All patients had a diagnosis of HPP clinically, biochemically, and genetically. The diagnosis of HPP required that all of the following criteria be met at the first admission: 1) a medical history or physical examination consistent with one or more dento-osseous complication(s) of HPP; 2) no evidence of any other condition that could cause the early loss of primary teeth; and 3) a serum ALP activity level below the age-matched reference ranges \[[@bb0040]\]. Physical and dental histories were recorded through a diagnostic interview process. Dental examinations were carried out at Department of Plastic Surgery, Division of Pediatric Dentistry & Orthodontics, Fujita Health University of Medicine. Clinical signs and symptoms were evaluated based upon a physical and oral examination, and the available medical or dental records. Biochemical and radiographic tests were performed at diagnosis. The serum ALP, PLP, Ca, phosphorus, parathyroid hormone (PTH), total serum IgE and 1,25-OH vitamin D levels, and the urine PEA levels on a spot urine test, were evaluated in all patients. The reference values for serum ALP, serum PLP/PL and urine PEA were obtained from Tanaka et al. \[[@bb0045]\], Akiyama et al. \[[@bb0050]\] and SRL Inc., respectively. A high total serum IgE was defined as a level higher than the adult standard value (\>250 IU/mL). Short stature was defined as a height below -2SD. Non atopy was defined as no evidence of pruritic skin, including no reporting by a parent of any rubbing or scratching by the child \[[@bb0055]\].

Bone mineral density (BMD) was measured at the level of the lumbar spine (L2-L4) using dual-energy X-ray absorptiometry. BMD *Z*-scores were calculated using data from a general population of Japanese children and adolescents (BMD of the lumber spine and total body mass) after adjusting for age. However, because these prior data do not include children under 6 years of age, the *Z*-scores were calculated for our current study patients 1 and 2 only.

2.3. ALPL gene analysis {#s0025}
-----------------------

*ALPL* gene analysis was performed with informed consent. DNA was extracted from peripheral blood samples and sequenced using the Sanger method to screen for genetic variations at the nucleotide level throughout all coding exons of the *ALPL* gene. We used the UCSC genome browser (<http://genome-asia.ucsc.edu/human> GRCh38/hg38) as the human genome assembly. PCR was carried out in a 10 μL volume containing 5.7 μL of distilled water, 2 μL of 5☓PrimeSTAR GXL buffer (TaKaRa, Japan), 0.2 μL of each primer (10 μM), 0.1 μL of PrimeSTAR GXL DNA polymerase (TaKaRa, Japan), and 1 μL of template DNA (20 ng/μL). The primer sequences are listed in the Online Supplementary Table. PCR amplifications were performed using a DNA thermal cycler (Applied Biosystems) under the following cycling conditions: initial denaturation at 94 °C for 2.5 min followed by 35 cycles at 98 °C for 10s, 60 °C for 15 s and 68 °C for 45 s. The PCR products were sequenced using a standard Sanger method. The *ALPL* sequence from the HPP patients was compared to control subjects and the reference *ALPL* sequence (Ref Seq NM_000478.5). Allele frequencies were investigated via gnomAD browser beta (<http://gnomad.broadinstitute.org/>). In silico analysis was performed using PolyPhen and SIFT.

2.4. 3D-modeling {#s0030}
----------------

A 3D model of the TNSALP molecule was previously constructed using the homology between TNAP and human placental alkaline phosphatase, which has a determined crystal structure. The locations of the mutations were determined using the UCSF Chimera ([www.cgl.ucsf.edu/chimera](http://www.cgl.ucsf.edu/chimera){#ir0020}).

3. Results {#s0035}
==========

3.1. Clinical evaluations {#s0040}
-------------------------

The chief complaints at diagnosis were premature loss of deciduous teeth in patients 1 to 4 and permanent teeth loss in patient 5. The dental features of these cases are summarized in [Table 1](#t0005){ref-type="table"}. All of the study patients had premature loss of their anterior deciduous teeth and atrophy of the alveolar bone. Permanent tooth loss was found in patient 5 only, but the mobility of permanent teeth was also evident in patient 1. Elongation of teeth and enamel hypoplasia were observed in 2 and 3 of the 5 patients, respectively. The results of biochemical of radiographic testing, and the clinical findings other than the dental features at diagnosis, for all 5 study patients are presented in [Table 2](#t0010){ref-type="table"}. Our present cases had been referred to our hospital in the first instance due to a single symptom i.e. the premature loss of deciduous teeth. After a detailed interview and examination however, other characteristic symptoms, and biochemical and radiographic findings, became evident as follows: dysphagia (1/5), headache (1/5), muscle ache (1/5), bone fractures (2/5), asthma (3/5), low serum ALP levels (5/5), high serum PLP/PL (5/5), high urine PEA levels (5/5), high serum IgE (4/5), flared metaphyses (1/5), and low *Z*-score BMD (2/2). All of our study patients showed serum ALP levels at \>30% below the lower limit of the age equivalent normal range. The serum PLP/PL and urine PEA levels were higher in all of our HPP patients compared to the control subjects. The BMD was measured in four patients, of whom two patients showed a low Z-score but this could not be calculated in the remaining two cases because their age were under 6.Table 1Dental features of the study patients.Table 1Dental featuresPatient 1Patient 2Patient 3Patient 4Patient 5Age at diagnosis9 y7 y1 y4 y39 yPremature loss of anterior deciduous teeth+++++Premature loss of posterior deciduous teeth+Mobility−−+Loss of permanent teethMobility−-[a](#tf0005){ref-type="table-fn"}-[a](#tf0005){ref-type="table-fn"}+, MobilityDelay of eruption−−−−−Atrophy of alveolar bone+++++Elongation of teeth−+−−+Enamel hypoplasia+−++−[^1]Table 2Clinical, biochemical and radiographic data for the study patients. N/A, not available. Reference values: Serum ALP from Tanaka et al. \[[@bb0045]\]; Serum PLP and PL from Akiyama et al. \[[@bb0040]\]; urine PEA from SRL Inc. For serum ALP, reference values are shown for patients over 20 years of age. For serum PLP and PL, reference values for 7--17 year-old patients are shown.Table 2Patient IDPatient 1Patient 2Patient 3Patient 4Patient 5Age1081439GenderFemaleMaleFemaleFemaleFemale  Biochemical testCa (mg/dl)9.7 (Reference: 8.7--10.3)9.8 (8.7--10.3)11.1 (8.7--10.3)10.4 (8.7--10.3)9.7 (8.7--10.3)Phosphorus (mg/dl)5.3 (2.5--4.7)5.9 (2.5--4.7)7.5 (2.5--4.7)4.9 (2.5--4.7)4.3 (2.5--4.7)ALP (U/L)228 (470--1450)245 (450--1300)155 (395--1289)286 (430--1150)50 (120--340)PTH (pg/ml)31 (15--65)27 (15--65)8 (15--65)21 (15--65)32 (15--65)1,25-OH vitD (pg/ml)62.2 (20--70)58.1 (20--70)88.3 (20--70)61.2 (20--70)57.2 (20--60)PLP (pyridoxal-5′-phosphate)(nmol/L)469.9 (14.5--57.3)322.5 (14.5--57.3)375.2 (16.2--57.4)325.9 (16.2--57.4)89.9 (14.5--57.3)PL (pyridoxal)(nmol/L)39.9 (7.4--17.7)28.8 (7.4--17.7)27.2 (8.8--28.0)43.8 (8.8--28.0)6.7 (7.4--17.7)PLP/PL11.811.213.87.413.3Total IgE (IU/ml)638.4349.5267.5109917.1Urine PEA (μmol/g Cr)480.1 (39.4--93.5)720.6 (29.1--75.6)662.7 (39.4--93.5)507.7 (39.4--93.5)274.7 (39.4--93.5)  Clinical findings without dental featuresShortening or deformity of the extremities−−−−−Bone fractures (NO.)10001Part of fracturesForearmRight shoulderSeizure−−−−−Enlargement of the anterior fontanelle−−−−−Renal calcification−−−−−Stature (cm)130 **(−1.4SD)**123 **(−0.2SD)**71.5 **(−1.9SD)**100.4 **(−0.85SD)**148.1 **(−1.96SD)**Body weight (kg)28.8 **(−0.7SD)**23.9 **(−0.1SD)**8.29 **(−1.9SD)**15.5 **(−0.9SD)**35.9Deafness−−−−−Asthma+++−−Atopy−−−−−Muscle ache−+−−−Dysphagia−−+−−Other symptom−−−−Headache  Radiographic findingsHypomineralisation−−−−−Deformity of long bones−−−−−Flared metaphyses−−+−−Narrow thorax−−−−−Bone mineral density (g/cm^2^)0.644 **(*Z*-score** **−** **1.2)**0.551 **(Z-score** **−** **1.8)**0.2980.395N/A  BirthGestational age39w5d38w0d38w2d39w6dN/ABirth weight (g)2786 **(−0.5SD)**2770 **(−0.4SD)**2405 **(−1.1SD)**2538 **(−1.4SD)**N/ABirth stature (cm)47 **(−1.2SD)**48.5 **(0.2SD)**48 cm **(−0.2SD)**49 **(−0.2SD)**N/ABirth head circumference (cm)30 **(−2.5SD)**33 **(0.0SD)**N/A31.4 **(−1.5SD)**N/ABirth chest circumference (cm)3131N/A30N/A

3.2. Gene analysis {#s0045}
------------------

The results of our *ALPL* mutation sequencing analyses are presented in [Table 3](#t0015){ref-type="table"}. The clinical forms of the genotypes were described previously \[[@bb0060], [@bb0065], [@bb0070], [@bb0075]\]. The three families in our current series all harbored different mutations that are rare within the general population, and had a minor allele frequency ranging from completely unreported to 0.00003716 (gnomAD browser beta). Family 1 (patients 1 and 2) members carried the compound heterozygous *ALPL* variants c.1183A\>G (p.Ile395Val) and c.1559delT (p.Leu520Argfs). The c.1183A\>G (p.Ile395Val) mutation was reported previously to result in a prenatal benign phenotype as the gene product still possessed residual ALP activity of 19.1% \[[@bb0080]\]. The c.1559delT (p.Leu520Argfs) variant is a null mutation that was previously reported to be common in Japanese severe HPP patients \[[@bb0085]\].Table 3Genotype-phenotype correlations within the HPP families examined in this study.Table 3Mode of inheritanceFamily 1 (patients 1 and 2)Family 2 (patient 3)Family 3 (patients 4 and 5)ARARARADGenotypec.1183A\>G(p.Ile395Val)c.1559delT(p.Leu520Argfs)c.283G\>A(p.Val95Met)c.1471G\>A(:p.Gly491Arg)c.1366G\>A(p.Gly456Arg)In silico function (PolyPhen)0.5350.89710.945In silico function (SIFT)0.080.1200Clinical form of the genotypePrenatal benignInfantileUnknownPerinatalInfantilePrevious reportWenkert et al. 2011Orimo et al. 1994NovelMornet et al. 1998Ozono et al. 1996Prevalence (% east Asia/total)0.002031/ 00.0008803/ 0.011870.003716/ 00/00/0ACMG evaluationLikely pathogenicPathogenicLikely pathogenicLikely pathogenicPathogenicPosition in the 3D structureInterface of homodimerUnclear lesionInterface of homodimerSurface of proteinInterface of homodimer

Family 2 (patient 3) was found to harbor compound heterozygous variants including c.283G\>A (p.Val95Met) and c.1471G\>A (p.Gly491Arg). Mutation c.283G\>A (p.Val95Met) was registered previously in a public database (Institute of Human Genetics, University Of Wurzburg), and classified as "with likely pathogenic" in ClinVar, but no clinical information has been reported to date for this variation. Analysis of the Val95Met substitution using SIFT and PolyPhen prediction software indicated that this mutation was 'tolerable' and 'possibly damaging', with scores of 0.12 and 0.897, respectively. In contrast, c.1471G\>A (p.Gly491Arg) is reported to be a severe perinatal phenotype mutation \[[@bb0070]\]. These data suggest that the c.1471G\>A (p.Gly491Arg) mutation may be null whereas the gene product harboring the c.283G\>A (p.Val95Met) variation may still possess residual enzymatic activity.

Family 3 (patients 4 and 5) had only one heterozygous mutation, c.1366G\>A (p.Gly456Arg), which had been initially reported as one of the compound heterozygous mutations in the infantile form of HPP \[[@bb0075]\], Furthermore, a recent study using transfection experiments has indicated that this mutation has a dominant-negative effect \[[@bb0090]\].

3.3. 3D-modeling {#s0050}
----------------

The locations of the identified mutated residues in the 3D structures of human TNSALP are presented in [Fig. 1](#f0005){ref-type="fig"}. In contrast to the severe Gly491Arg mutation located at the surface of this protein, the three mutations that characterized the mild HPP cases in our present study (Val95Met, Ile395Val and Gly456Arg) were all localized at the homodimer interface. Severe collisions between the side chains were predicted in the Gly456Arg variant ([Fig. 2](#f0010){ref-type="fig"}a), whereas a mild only and no effect were predicted for the Val95Met and Ile395Val mutations, respectively ([Fig. 2](#f0010){ref-type="fig"}b, c).Fig. 13D strand view of the human TNSALP protein. The two monomers are denoted by Chain A and Chain B. The three amino-acid residues that were found to be mutated in our mild HPP cases (G456R, V95M, I395V) are localized on the homodimer interface. Gly491Arg is located on the surface of the protein. Leu520Argfs is located within the region where the 3D structure has not yet been clearly determined.Fig. 1Fig. 2Structural models of the human TNSALP protein. (a) Gly456 is located at the homodimer interface. Severe collisions between the side chains occur in the case of Gly456Arg (green).(b) Val95 is located at the homodimer interface. Mild collisions occur in the case of Val95Met (green).(c) Ile395 is located at the homodimer interface. No significant changes occur in the case of Ile395Val (green). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 2

4. Discussion {#s0055}
=============

One of the characteristic findings in our present study series of 5 patients was the high percentage of coexisting asthma (3/5) as well as high level serum IgE (4/5). In addition, 3 out of the 4 patients with a high serum IgE had asthma. Tracheomalacia is a known symptom of perinatal lethal HPP \[[@bb0025]\] but the frequency of other clinical conditions associated with wheezing in these cases, such as asthma and the serum IgE level, have remained unknown. Although we examined only a very small cohort of patients in our present study, more than half of these cases showed a past or current medical history of asthma and a high serum IgE. These characteristics may account for the fragility of tracheal tissues and a predisposition to asthma in mild HPP patients. Although the treatment approaches for HPP have historically been supportive in nature, enzyme replacement therapy (ERT) has recently become available for these patients using asfotase alfa (Strensiq™), a bone-targeting recombinant alkaline phosphatase \[[@bb0095]\]. This enzyme has produced beneficial effects in terms of survival and function in HPP patients \[[@bb0100],[@bb0105]\]. However the selection of appropriate candidates for this ERT has remained challenging when the condition is not life-threatening \[[@bb0095]\]. The loss of permanent teeth has a detrimental impact on quality of life but no study has demonstrated the effectiveness of an early ERT in preventing this outcome in mild HPP. Further studies are needed to assess the efficacy of these therapies.

Our present mutational analysis identified compound heterozygous mutations in family 1, i.e. one obvious loss-of-function mutation (1559delT) and one variant that still possessed some residual enzymatic activity (Ile395Val). In family 2, one identified mutation (Gly491Arg) was previously described as severe, and another (Val95Met) to have only weak effects, by in silico functional data. Since the phenotype of patient 3 in this family was mild, it is possible that Val95Met may possess some residual ALP activity in this case. Family 3 harbored only one mutation (Gly456Arg) with an autosomal dominant transmission. This variant was reported previously to have a dominant-negative effect in vitro, although our present study is the first to clinically demonstrate Gly456Arg as autosomal dominant. Hence, the genotype of mild HPP can be classified as either 1) compound heterozygous for a severe and hypomorphic mutation; or 2) dominant-negative mutations. In family 1, two patients harboring the same mutations seemed to manifest a similar degree of disease severity. In family 3, patient 5 is the mother of patient 4 harboring the same mutation and had similar symptoms in her own childhood. Hence, a genotype-phenotype correlation was present in our current cases. Genetic testing for these genotypes will assist with genetic counseling.

The mechanisms underlying the effects of the mutations in our current study series, i.e. the reasons for a dominant or recessive effect, are still unclear. However, interactions between the monomers of the dimeric TNSALP protein structure are likely to be involved \[[@bb0110]\]. TNSALP has five regions (the active site and its vicinity, the active site valley, the homodimer interface, the crown domain, and the calcium-binding domain), which are crucial for enzyme function and bone mineralization \[[@bb0115]\]. It was previously reported that the TNSALP mutations identified to date with a dominant effect are restricted to three regions of the protein: the active site, homodimer and crown domain. However the difference between the standard recessive mutation and these dominant mutations is still unknown. A prevailing hypothesis is that the dominant-negative effect may be due to the inhibition of the wild-type monomer by a mutated monomer in the heterodimer, or the sequestration of the wild-type protein by a mutant product in the Golgi apparatus that prevents it from being transported to the membrane \[[@bb0120]\]. In our current analysis, three of the identified mutations were located at the homodimer interface, but the Gly456Arg mutation showing a dominant-negative effect produced the most severe change in 3-D modeling. TNSALP Gly456Arg variants may maintain monomer interactions and might directly affect the enzymatic activity of dimers, including those harboring mutations, whilst the dimers from normal monomers would maintain small amounts of enzymatic activity. In contrast, the dimers of the proteins containing the hypomorphic mutations identified in families 1 and 2 (Ile395Val, Val95Met) could maintain low levels of enzymatic activity because of the lesser impact of these variations compared to Gly456Arg. Future investigations of the differences in the 3D structures of TNSALP variants may reveal the precise mechanisms underlying dominant-negative and recessive but weak mutation effects.
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The sequences of the primers used in *ALPL* gene analysis.Image 1
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[^1]: Deciduous dentition.
